Biotechnology Reagents & Kits Market Demand, Size, Report to 2032
The global biotechnology reagents & kits market size was exhibited at USD 398.56 billion in 2022 and is projected to hit around USD 1,999.27 billion by 2032, growing at a CAGR of 17.5% during the forecast period 2023 to 2032.
Key Pointers:
Biotechnology Reagents & Kits Market Report Scope
|
Report Coverage |
Details |
|
Market Size in 2023 |
USD 468.31 Billion |
|
Market Size by 2032 |
USD 1,999.27 Billion |
|
Growth Rate From 2023 to 2032 |
CAGR of 17.5% |
|
Base Year |
2022 |
|
Forecast Period |
2023 to 2032 |
|
Segments Covered |
Kit type, Technology, Tested parameters, Micro-organisms, Purpose, End use |
|
Market Analysis (Terms Used) |
Value (US$ Million/Billion) or (Volume/Units) |
|
Regional Scope |
North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
|
Key Companies Profiled |
Thermo Fisher Scientific; QIAGEN; New England Biolabs; Illumina, Inc.; Agilent Technologies, Inc.; Bio-Rad Laboratories; F. Hoffmann-La Roche Ltd.; Merck KGaA; Promega Corp.; Takara Bio, Inc.; LGC Ltd.; Toyobo Co. Ltd. |
The Key factors driving the market include the introduction of novel and advanced products, a rise in investments in the biotechnology sector, and increasing demand for synthetic biology.
Increasing research and development expenditure for life sciences and biotechnology research is expected to drive the market significantly in the coming years. Over the past few decades, the biotechnology sector has witnessed a paradigm shift toward new treatments & drugs, biologically controlled production processes, genetically modified foods, biologically based computing, and new materials, thereby propelling the market growth.
Advancements in molecular diagnostic techniques, such as droplet digital PCR, NGS, and genome-wide sequencing with respect to accuracy, reproducibility, and timeline, have influenced the adoption of biotechnology reagents & kits in the market. The advent of long-read sequencing has made sequencing of longer strands of DNA possible by only reading single DNA molecules, in turn, driving the market growth.
Cell culture technology accounted for the largest revenue share in 2022 owing to the vast product portfolio offered by the key entities and expanding cell biology research. RNA-Seq using NGS technology has emerged as the method of choice for research communities investigating the transcriptome. The virus segment dominated the market in 2022 with increased adoption in cell & gene therapies and vaccinology. The ongoing pandemic has positively impacted the market growth as focused efforts are being conducted for vaccine development using viral vectors.
Kit Type Insights
The detection kits segment dominated the market in 2022 with a revenue share of over 25.9%. This can be attributed to the widespread utilization of detection kits at various end-use settings, such as healthcare, industrial processing, food, and agriculture. With the growing need to curb the COVID-19 virus, the production of detection kits has increased over the past few months.
For instance, in May 2021, the Defence Research and Development Organisation’slaboratory, the Defence Institute of Physiology and Allied Sciences (DIPAS), introduced an antibody-dependent kit DIPCOVAN DIPAS-VDx SARS-CoV-2 IgG antibody Microwell ELISA for sero-surveillance. This kit can recognize both Spikes and Nucleocapsid (S&N) protein of coronavirus with 97% sensitivity and 99% specificity. The detection kit is manufactured in collaboration with Vanguard Diagnostics Private Limited.
Increasing demand for molecular diagnostics is a major factor contributing to the growth of amplification kits. Biotechnology and healthcare companies have increased the production of RT-PCR-based testing kits due to the rapid rise in the number of COVID-19 cases around the world. For instance, in January 2021, New England BioLab, Inc. launched the Luna SARS-CoV-2 RT-qPCR Assay Kit for the detection of SARS-CoV-2 nucleic acid.
Technology Insights
Cell culture technology dominated the market with a revenue share of more than 27% in 2022 and is followed by Polymerase Chain Reaction (PCR) technology. Increasing demand for cell culture reagents by the research community is driving the segment growth. The comprehensive portfolio of cell culture media and reagents owned by companies has supplemented the market growth.
PCR is one of the key technologies used for the detection and analysis of specific gene sequences. Currently available real-time PCR assays offer high specificity and sensitivity, and are, thereby, considered the go-to methods for various genomic studies. Currently, the PCR technique is considered the most accurate, for the detection of COVID-19, leading to a significant increase in the adoption of PCR testing kits and reagents.
Next-Generation Sequencing (NGS) is now considered a reliable and powerful tool for the characterization of cell lines used for the production of gene therapy, vaccines, and recombinant proteins. Thus, with the advancements in sequencing techniques, the market for sequencing reagents is anticipated to witness significant growth over the forecast period.
Tested Parameters Insights
The RNA segment accounted for the largest revenue share of over 32% owing to the increasing research on transcriptomics. Research on extracellular RNA for clinical diagnosis has increased over the past five years. Companies and universities are entering the field for the development of RNA-based therapeutics by the virtue of transcriptomic technologies. Key industry participants are constantly introducing new products to drive the market. For instance, in March 2021, PromegaCorp. launched XpressAmp Direct amplification reagent.
It enables RNA extraction-free sample preparation, which is automation-friendly. Such advancements are expected to drive market growth.DNA testing has significant application in newborn genetic screening, identity diagnostics & forensics, pharmacogenomics diagnostic testing, and drug metabolism, which is expected to drive the segment growth. Increasing demand for DNA diagnostics technology is the major driver of this segment.
Micro-Organisms Insights
The virus segment accounted for the highest revenue share of over 34% in 2022, which is closely followed by the bacteria segment. The dominance of the segment can be attributed to the increasing application of viruses in gene therapy and vaccinology. Increasing R&D to support the use of recombinant viral vectors in vaccine development further drives the segment.
Furthermore, the outbreak of SARS-COV-2 infection acts as a driving factor for the market as there is an increase in demand for viral reagents, which is propelling the segment growth. The rising number of SARS-CoV-2 cases has fueled the demand for tests and reagents for testing as well as research purposes, thereby driving developments in the segment.
The use of therapeutic bacteria has revolutionized cancer management by enabling addressing certain limitations associated with conventional cancer therapies like surgery, radiotherapy, chemotherapy, and immunotherapy. Bacteria alone have the potential to act as anticancer agents. Such factors are anticipated to boost the segment growth over the forecast period.
Purpose Insights
The on-site purposes segment led the market in 2022 with a revenue share of over 58%. The rising utilization of Point-of-Care (POC) testing has primarily driven the segment growth. Efficient and timely POC testing based on the availability of POC reagents has supplemented the segment growth.
On-site testing applications in the food and beverage industry also aided the market expansion. It includes microbiological on-site testing and enzymatic on-site testing. Microbiological on-site testing is used in the detection of viruses, bacteria, and molds in food. Enzymatic on-site testing is used in the measurement of constituents, such as acid or alcohol and sugar in foods. This test is essential when analyzing beverage and dairy products.
A broad variety of research reagents contribute to the growth of various fields in science and medicine. Laboratory reagents are employed in various assays and methodologies, such as to support Immunohistochemistry (IHC), cell culture, flow cytometry, cell selection, flow cytometry, protein purification, immunodepletion, and others. In vitro reagents are crucial in clinical chemistry and testing laboratories.
End-use Insights
The healthcare sector dominated the market in 2022 with a revenue share of over 53%. The segment will retain the leading position throughout the forecast years owing to the ongoing clinical trials and research & development activities for clinical diagnostics. Moreover, a shift in preference toward molecular diagnostics and personalized medicine has increased mergers and collaborations for developing novel technology.
This has subsequently driven the demand for various advanced products in the healthcare sector. For instance, in March 2022, Roche and GenMark diagnostics entered into a merger agreement to introduce innovative technology to test a wide range of pathogens with one patient specimen. GenMark’sePlex platform provides quick and effective results.
The rising penetration of biotechnology tools to create traits of organisms including animals, plants, as well as microbes for yield, size, and color is propelling the market growth for the food & agriculture segment. Furthermore, the advancements in plant tissue culture techniques and recombinant DNA technology have drastically changed the agriculture sector leading to significant market growth.
Regional Insight
North America dominated the global market with a revenue share of more than 39% in 2022. The presence of key players actively developing technologically advanced novel products coupled with the introduction of several new products by emerging start-ups has majorly contributed to the dominance of the region.
The U.S.-based players and organizations are continuously involved in high-quality life science research, thereby affecting ancillary markets. Various strategic initiatives by key companies to maintain regional presence and market share enhance the competition. For instance, in March 2022, Agilent technologies acquired Resolution Bioscience Inc., a liquid biopsy firm, to offer an NGS-based noninvasive liquid biopsy test platform, in turn, strengthening its genomics business.
Asia Pacific is anticipated to be the fastest-growing regional market over the forecast period. The growing disposable income, improving diagnostics & therapeutic infrastructure, and increasing research activities for the development of effective therapeutics are some key factors that have driven the market growth in Asia Pacific.
Some of the prominent players in the Biotechnology Reagents & Kits Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Biotechnology Reagents & Kits market.
By Kit Type
By Technology
By Tested Parameters
By Micro-Organisms
By Purpose
By End-use
By Region
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers